Garetosmab (DB16379): A Comprehensive Review of an Investigational Anti-Activin A Antibody for Fibrodysplasia Ossificans Progressiva and Other Potential Indications

1. Introduction to Garetosmab and Fibrodysplasia Ossificans Progressiva (FOP)

1.1. Overview of Garetosmab

Garetosmab is an investigational, fully human monoclonal antibody of the immunoglobulin G4 kappa (IgG4κ) isotype, designed to target and neutralize Activin A.[1] Its primary therapeutic application under investigation is for the management of fibrodysplasia ossificans progressiva (FOP), a rare and severely disabling genetic disorder.[1] Beyond FOP, Garetosmab is also being explored for its potential in other conditions, notably obesity, reflecting a broader interest in the physiological roles of Activin A.[2]

1.2. Pathophysiology of Fibrodysplasia Ossificans Progressiva (FOP)

Fibrodysplasia ossificans progressiva is an exceptionally rare, autosomal dominant genetic disorder characterized by episodic and progressive heterotopic ossification (HO).[1] This pathological process involves the formation of mature, lamellar bone in extraskeletal soft tissues, including muscles, tendons, ligaments, and fascia.[1] Flare-ups, which are episodic inflammatory events often precipitated by trauma (including minor tissue damage, immunizations, or viral illnesses), typically precede and trigger ossification of the affected lesion.[1]

The consequences of progressive HO are devastating. Patients experience abnormal cartilage formation, growth plate dysplasia, and severe joint ankylosis, leading to cumulative and irreversible loss of mobility.[1] This progressive immobility results in significant disability, with many patients becoming wheelchair-bound or confined to fixed positions, and is associated with numerous comorbidities, including restrictive lung disease, difficulties with mastication and nutrition, and a markedly curtailed lifespan.[5]

The genetic underpinning of FOP is primarily a recurrent missense mutation in the Activin A receptor type 1 (ACVR1) gene, also known as activin receptor-like kinase 2 (ALK2).[1] Approximately 97% of individuals with FOP share the same heterozygous c.617G>A substitution, resulting in an arginine to histidine change at amino acid position 206 (R206H) in the ACVR1 protein.[1]

1.3. The Role of ACVR1 and Activin A in FOP Pathogenesis

The ACVR1 receptor is a type I transmembrane serine/threonine kinase that plays a crucial role in bone morphogenetic protein (BMP) signaling pathways, which are essential for embryonic development and postnatal bone homeostasis. Under normal physiological conditions, Activin A typically signals through a complex involving the type I receptor ACVR1B (ALK4) and type II receptors (ACVR2A, ACVR2B, or BMPR2), primarily activating the Smad2/3 signaling pathway.[1] Activin A can also form a non-signaling complex with wild-type ACVR1, which appears to antagonize ACVR1-mediated BMP signaling.[1]

The pathogenic R206H mutation in ACVR1 fundamentally alters its ligand specificity and signaling response. This specific mutation renders the ACVR1 receptor aberrantly responsive to Activin A.[1] In the context of FOP, Activin A binding to the mutant ACVR1 (R206H) receptor leads to its pathological activation and subsequent phosphorylation of Smad1/5/8 proteins.[1] This aberrant signaling cascade drives chondrogenesis and the subsequent endochondral ossification characteristic of FOP lesions.[5] This "gain-of-function" alteration, where Activin A is transformed from a ligand that does not typically activate ACVR1-mediated osteogenic pathways (and may even inhibit them) into a potent agonist for pathological bone formation, represents the central molecular derangement in FOP. The discovery of this pathogenic ligand-receptor interaction identified Activin A as a key and specific therapeutic target for FOP.[1]

The profound severity and relentless progression of FOP, coupled with the historical lack of any approved curative or disease-modifying therapies until the recent advent of palovarotene, have highlighted a significant unmet medical need.[3] The devastating impact on patients' physical function, quality of life, and survival underscores the urgency for developing effective and safer treatments like Garetosmab, which aim to interrupt the core disease mechanism.

2. Molecular Profile and Developer of Garetosmab

2.1. Chemical and Biologic Classification

Garetosmab is classified as a biotechnology-derived therapeutic, specifically a protein-based therapy.[1] It is a fully human monoclonal antibody (mAb).[1] The antibody is of the IgG4 subclass with a kappa (κ) light chain (IgG4κ).[1] The choice of the IgG4κ isotype is significant; IgG4 antibodies are characterized by their reduced ability to mediate effector functions such as antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) compared to other IgG subclasses like IgG1. This property is often sought for therapeutic antibodies designed to neutralize soluble ligands or block receptor interactions, as the primary goal is target engagement and antagonism without inducing potentially harmful inflammatory responses or cell killing. For a chronic condition like FOP requiring long-term treatment, minimizing such immune-mediated side effects from the antibody itself is a critical consideration in its design.

The molecular weight of Garetosmab is reported to be approximately 146 kDa [11], a typical size for an IgG molecule. Its sequence origin is human, which is intended to minimize immunogenicity when administered to patients.[12]

2.2. Synonyms and Identifiers

Garetosmab is identified by several names and codes across scientific literature and databases:

• Generic Name: Garetosmab [1]
• DrugBank Accession Number: DB16379 [1]
• CAS Number: 2097125-54-5 [1]
• Synonyms/External IDs: The most prominent synonym is REGN2477. Other related identifiers include REGN-2477, R2477, and R-2477.[1]
• Global Substance Registration System (GSRS) Unique Ingredient Identifier (UNII): KR9ZSKO5QE [12]

These identifiers are essential for accurate tracking and cross-referencing of information regarding Garetosmab in research, clinical trials, and regulatory documentation.

2.3. Developer Information

Garetosmab was originated and developed by Regeneron Pharmaceuticals.[3] Regeneron utilized its proprietary VelocImmune® technology in the discovery and generation of Garetosmab.[7] The VelocImmune® platform employs genetically engineered mice with humanized immune systems, capable of producing optimized, fully human antibodies. This technology aims to generate antibodies with high affinity and specificity for their targets while minimizing the potential for immunogenic reactions in patients, a crucial attribute for biologic therapies intended for chronic administration. The use of such advanced platforms reflects a commitment to developing refined and targeted antibody therapeutics.

Table 1: Garetosmab - Key Identifiers and Properties

Property	Detail	Source(s)
Generic Name	Garetosmab	1
DrugBank ID	DB16379	1
CAS Number	2097125-54-5	1
Type	Biotech, Monoclonal Antibody (human IgG4κ)	1
Developer	Regeneron Pharmaceuticals	3
Key Synonym	REGN2477	10
Molecular Weight	~146 kDa	11
Sequence Origin	Human	12
Primary Target	Activin A (Inhibin beta A chain)	1
Primary Indication (Investigational)	Fibrodysplasia Ossificans Progressiva (FOP)	1

3. Mechanism of Action of Garetosmab

3.1. Targeting Activin A

Garetosmab exerts its therapeutic effect by specifically targeting Activin A.[1] It is engineered to bind with high affinity and specificity to activins that contain the inhibin βA subunit. These include Activin A (a homodimer of two βA subunits, βA-βA), Activin AB (a heterodimer of βA and βB subunits), and Activin AC (a heterodimer of βA and βC subunits).[1] The molecular target within Activin A is the Inhibin beta A chain, encoded by the INHBA gene (UniProt ID: P08476).[1]

A critical aspect of Garetosmab's design is its selectivity. It does not bind to or functionally inhibit other members of the transforming growth factor-beta (TGF-β) superfamily that may utilize similar receptor pathways but have distinct physiological roles. These non-target ligands include Activin B (a βB-βB homodimer), inhibin A, BMP-2, BMP-6, BMP-9, BMP-10, growth differentiation factor 8 (GDF8, also known as myostatin), and GDF11.[11] This high degree of specificity is intended to selectively neutralize the pathological actions of Activin A in FOP while minimizing interference with the essential physiological functions mediated by other TGF-β/BMP family members. Such precision is paramount for achieving a favorable therapeutic window, particularly for a drug targeting a signaling pathway with broad biological relevance.

3.2. Impact on Aberrant ACVR1 Signaling in FOP

In the context of FOP, the R206H mutation in the ACVR1 receptor sensitizes it to pathological activation by Activin A.[1] By binding directly to Activin A, Garetosmab effectively sequesters the ligand, preventing it from interacting with and activating the mutant ACVR1 R206H receptor.[1] This blockade of Activin A-mediated signaling through the aberrant receptor is hypothesized to inhibit the downstream phosphorylation of Smad1/5/8 and the subsequent cascade of events leading to chondrogenesis and heterotopic ossification.[1]

The primary therapeutic objective of Garetosmab in FOP is to mitigate both the acute, painful inflammatory flare-ups that often precede new bone formation and to halt or significantly reduce the progressive development of new HO lesions.[1] By specifically neutralizing Activin A, the therapy aims to normalize the aberrant signaling pathway at the root of FOP pathogenesis, ideally without disrupting the normal physiological functions of the broader TGF-β/BMP signaling network, owing to its aforementioned ligand specificity.[1]

While the targeted inhibition of Activin A's pathological role in FOP is well-defined, it is important to acknowledge that Activin A itself is a pleiotropic cytokine with diverse physiological roles. These include involvement in inflammation, reproductive processes, erythropoiesis, nerve cell survival, and normal bone growth.[1] Systemic, long-term inhibition of Activin A, even with a highly specific antibody like Garetosmab, could potentially interfere with these normal functions. Some adverse events observed in clinical trials, such as madarosis (loss of eyelashes or eyebrows) and certain skin and soft tissue issues [5], might theoretically be related to the interference with Activin A's physiological roles in tissue homeostasis (e.g., in skin and hair follicle biology). This highlights the inherent complexity and potential for on-target, off-tissue effects when developing therapies against molecules with widespread biological activities, necessitating careful long-term safety monitoring.

4. Pharmacokinetics (PK) and Pharmacodynamics (PD)

4.1. Pharmacokinetics

The pharmacokinetic profile of Garetosmab has been characterized in healthy female volunteers and, to some extent, in patients with FOP.

Absorption & Bioavailability:

• Intravenous (IV) Administration: Following single IV doses in healthy females ranging from 0.3 mg/kg to 10 mg/kg, Garetosmab exhibited dose-proportional increases in mean peak plasma concentrations (Cmax).[1] The Cmax values ranged from 8.10±0.929 mg/L at the 0.3 mg/kg dose to 378±39.7 mg/L at the 10 mg/kg dose. The time to reach Cmax (Tmax) was rapid, with a median of 0.06 to 0.10 days post-infusion. The area under the plasma concentration-time curve from time zero to infinity (AUC0-∞) ranged from 72.2±15.4 mg⋅day/L at 0.3 mg/kg to 7520±809 mg⋅day/L at 10 mg/kg.[1]
• Subcutaneous (SC) Administration: A single subcutaneous dose of 300 mg in healthy females resulted in a Cmax of 31.6±7.94 mg/L, achieved at a median Tmax of 20.9 days (range 6.88-21.0 days). The AUC0-∞ for this SC dose was 1334±376 mg⋅day/L.[1] As expected for monoclonal antibody administration, the SC route showed slower absorption and a lower Cmax compared to IV administration, which could offer potential advantages for dosing frequency or patient convenience if this route were further developed.

Distribution:

The steady-state volume of distribution (Vd_ss) of Garetosmab, following single IV doses of 0.3-10 mg/kg in healthy women, was reported to be between 41.4±4.66 ml/kg and 47.8±4.70 ml/kg.1 These values are relatively small, suggesting that the distribution of Garetosmab is primarily confined to the vascular and interstitial compartments, which is typical for large protein therapeutics like monoclonal antibodies.

Metabolism & Elimination:

Detailed information on the specific metabolic pathways and routes of elimination for Garetosmab is not available from the provided data.1 However, like other monoclonal antibodies, Garetosmab is expected to be metabolized via general protein catabolism into smaller peptides and amino acids.

A key feature of Garetosmab's pharmacokinetics is its nonlinear clearance. Clearance (CL) was observed to decrease with increasing doses when administered as a single IV infusion to healthy women. For instance, CL was 4.35±1.11 mL/day/kg at a 0.3 mg/kg dose, decreasing to 1.34±0.149 mL/day/kg at a 10 mg/kg dose.[1] This dose-dependent clearance is indicative of target-mediated drug disposition (TMDD).[2] TMDD occurs when a significant fraction of the drug is eliminated through high-affinity binding to its pharmacological target (in this case, Activin A) and subsequent internalization and degradation of the drug-target complex. At lower drug concentrations, this target-mediated pathway can become saturated, leading to a disproportionate increase in drug exposure with increasing doses. Understanding TMDD is crucial for dose selection, as achieving and maintaining target saturation is often necessary for optimal therapeutic efficacy. Dosing regimens must be designed to overcome this effect, particularly in the initial treatment phase.

Half-life (T½):

An explicit terminal half-life for Garetosmab is not provided.1 However, the presence of TMDD implies that the apparent half-life will be concentration-dependent and will likely increase with dose as target-mediated clearance pathways become saturated.

Steady State in FOP Patients:

In the LUMINA-1 clinical trial involving FOP patients, steady-state pharmacokinetic profiles were reportedly achieved 12–16 weeks after the first dose, with stable trough concentrations observed thereafter under an every-4-week dosing regimen.2 This timeframe (approximately 3-4 months) to reach steady state is consistent with monoclonal antibodies exhibiting TMDD and possessing a relatively long effective half-life once target saturation is achieved. This also suggests that the full clinical effects of the drug might take a similar period to manifest and stabilize.

4.2. Pharmacodynamics (PD)

Pharmacodynamic assessments have focused on confirming target engagement and understanding the dose-response relationship. First-in-human studies highlighted the nonlinear pharmacokinetics attributable to TMDD, which inherently supports a dose-response relationship.[2]

In FOP patients participating in the LUMINA-1 trial, changes in biomarker levels, specifically total Activin A, provided evidence consistent with target saturation at the higher doses of Garetosmab administered.[2] An increase in measured "total" Activin A levels following administration of a neutralizing antibody like Garetosmab is a recognized pharmacodynamic effect. This phenomenon can occur if the antibody-Activin A complex has a longer circulatory half-life than free Activin A, or if the assay used detects both free and antibody-bound ligand. It is important to interpret this as an indicator of target engagement by Garetosmab, rather than an increase in biologically active Activin A; indeed, the concentration of free, active Activin A is expected to decrease. Such PD markers are valuable for confirming that the drug is interacting with its intended target in vivo at clinically relevant exposures.

Table 2: Summary of Key Pharmacokinetic Parameters of Garetosmab (in Healthy Females)

Parameter	Dose Range / Single Dose	Route	Population	Value (Mean ± SD or Median)	Key Observation / Source(s)
Cmax	0.3−10 mg/kg	IV	Healthy Females	8.10±0.929 mg/L to 378±39.7 mg/L	Dose-proportional increase 1
	300 mg	SC	Healthy Females	31.6±7.94 mg/L	1
Tmax	0.3−10 mg/kg	IV	Healthy Females	0.06−0.10 days (median)	1
	300 mg	SC	Healthy Females	20.9 days (median, range 6.88−21.0)	1
AUC0-∞	0.3−10 mg/kg	IV	Healthy Females	72.2±15.4 mg⋅day/L to 7520±809 mg⋅day/L	1
	300 mg	SC	Healthy Females	1334±376 mg⋅day/L	1
Vd_ss	0.3−10 mg/kg	IV	Healthy Females	41.4±4.66 ml/kg to 47.8±4.70 ml/kg	1
Clearance (CL)	0.3−10 mg/kg	IV	Healthy Females	4.35±1.11 mL/day/kg to 1.34±0.149 mL/day/kg	Nonlinear (Target-Mediated Drug Disposition - TMDD) 1
Steady State (FOP Patients)	10 mg/kg Q4W (LUMINA-1)	IV	FOP Patients	Achieved in 12–16 weeks	2

5. Clinical Development for Fibrodysplasia Ossificans Progressiva (FOP)

The clinical development program for Garetosmab in FOP has encompassed early-phase studies in healthy volunteers and more extensive Phase 2 and Phase 3 trials in patients with FOP.

5.1. Early Phase Studies

A Phase 1 first-in-human study was conducted in healthy women with no childbearing potential.[2] This study evaluated single doses of Garetosmab administered via both intravenous (IV) and subcutaneous (SC) routes. Key findings from this initial trial included the demonstration of an acceptable safety profile, with no dose-limiting toxicities observed.[2] Furthermore, it provided foundational pharmacokinetic data, confirming dose-proportional mean peak concentrations with IV dosing and documenting the characteristic nonlinear elimination profile attributed to target-mediated clearance.[2] These results were crucial in establishing preliminary safety and understanding Garetosmab's disposition in humans, thereby paving the way for its investigation in FOP patients.

5.2. Phase 2 Studies: Detailed Analysis of the LUMINA-1 Trial (NCT03188666)

The LUMINA-1 trial (NCT03188666) represents the most significant Phase 2 study in the Garetosmab FOP clinical program.[2]

Study Design and Patient Population:

LUMINA-1 was a randomized, double-blind, placebo-controlled study that enrolled 44 adult patients, aged 18 to 60 years, diagnosed with FOP.2 These patients, recruited from North America and Europe, presented with varying degrees of disease severity, from localized movement restrictions to near-total immobility.18 The trial consisted of a 28-week double-blind treatment period during which patients received either Garetosmab (e.g., 10 mg/kg IV every 4 weeks) or placebo.2 This was followed by an open-label extension (OLE) period, where all participants, including those initially assigned to placebo who then switched, received active Garetosmab treatment.2

Efficacy Outcomes:

The primary efficacy endpoint for the 28-week double-blind period was the change in total lesion activity, encompassing both new and existing lesions, as assessed by 18F-Sodium Fluoride Positron Emission Tomography combined with Computed Tomography (18F-NaF PET-CT).2

• Garetosmab treatment resulted in an approximate 25% decrease in total lesion activity compared to placebo. This effect was primarily driven by a substantial reduction in new lesion formation. However, this primary endpoint narrowly missed statistical significance (p=0.0741).[2]

Despite the primary endpoint outcome, several secondary and other efficacy measures demonstrated promising effects:

• New Heterotopic Ossification (HO) Lesions: A striking reduction of approximately 90% in the volume and number of new HO lesions was observed in Garetosmab-treated patients compared to placebo during the 28-week period, as measured by both PET and CT scans.[2] Furthermore, during the second period of the study (the OLE), none of the participants who switched from placebo to Garetosmab developed new HO lesions.[2]
• Flare-ups: Patient-reported flare-ups were reduced by 50% in the Garetosmab group compared to placebo (nominal p=0.03).[7] Investigator-reported adverse events of flare-ups were significantly lower in the Garetosmab arm (10%) versus the placebo arm (42%).[7]
• Overall Impact: The LUMINA-1 study indicated that Garetosmab treatment effectively stopped new HO from developing in areas where it should not and also reduced the frequency of flare-ups. However, it did not lead to changes in existing, mature heterotopic bone.[5]

Safety Profile and Adverse Events:

During the LUMINA-1 trial, most treatment-emergent adverse events (TEAEs) were reported as mild to moderate in severity.18 All patients, in both Garetosmab and placebo groups during the double-blind phase, experienced TEAEs.2

• Commonly reported adverse events associated with Garetosmab included epistaxis (nosebleeds), madarosis (loss of eyebrows and/or eyelashes), and various skin and soft tissue infections.[2] Some skin abscesses were serious and required hospitalization, though affected patients continued on Garetosmab.[2]
• Patient Deaths: A significant safety concern arose from the occurrence of five patient deaths during the open-label extension period of the trial, at which point all participants were receiving Garetosmab.[2] It is important to note that no deaths were reported during the initial 28-week double-blind treatment period.[18]
• Initial assessments suggested that these fatalities appeared consistent with the known natural history of FOP, including common causes of death and life expectancy for patients with similar age and disease severity.[2] No clear pattern directly linked the deaths to Garetosmab's known mechanism of action.[5]
• However, a causal relationship between the deaths and Garetosmab treatment could not be definitively ruled out.[2] This uncertainty prompted Regeneron to pause dosing in the LUMINA-1 trial to allow for further investigation and a thorough review of the benefit-risk profile.[18] The occurrence of deaths in the OLE, where no contemporaneous placebo group existed for direct comparison of mortality rates over that specific extended period, complicates the causality assessment. While FOP itself carries a high burden of morbidity and mortality, the absence of a control group in the OLE makes it challenging to definitively ascertain whether the observed death rate in the Garetosmab-treated cohort was higher than what would be expected from the natural progression of the disease in a similar group of FOP patients.

Published Results:

The primary results of the LUMINA-1 trial were published in the peer-reviewed journal Nature Medicine on September 28, 2023.21 Clinical pharmacology findings from the trial were also published in the Journal of Clinical Pharmacology.21 To enhance accessibility for patients and their families, a plain language summary of the LUMINA-1 results was published in Future Medicine on April 11, 2024.6

The strong efficacy signal on preventing new HO formation was highly encouraging. However, the serious safety concerns, particularly the patient deaths, presented a significant challenge for the continued development of Garetosmab for FOP. This tension between apparent efficacy on a key disease manifestation and a serious, incompletely understood risk profile has been a defining feature of Garetosmab's FOP program.

5.3. Phase 3 Studies

Despite the challenges, Regeneron has proceeded with further Phase 3 investigation.

• OPTIMA Trial (NCT05318240): This Phase 3 trial was initiated in November 2022.[21] The OPTIMA trial design builds directly upon the outcome measures and insights gained from the LUMINA-1 study and other Phase 2 research.[2] Its primary objectives include confirming the suppression of new HO lesion formation and evaluating the overall reduction in disease progression in FOP patients.[2] Further information about this trial is available through dedicated trial resources like optimatrial.com.[21] The decision to proceed with OPTIMA suggests that Regeneron believes a favorable benefit-risk profile might still be established, potentially through refined patient selection, dosing, or enhanced safety monitoring.
• NCT04577820 (Study in Japanese Adult FOP Patients): This was a planned Phase 3 trial designed to assess the efficacy and safety of Garetosmab specifically in Japanese adult patients with FOP.[1] However, the status of this trial is listed as "withdrawn".[1] The explicit reasons for its withdrawal are not detailed in the available information, but it is plausible that this decision was influenced by the global safety review following the LUMINA-1 findings or other strategic considerations by the sponsor. The withdrawal of this trial after the emergence of safety signals from LUMINA-1 could reflect heightened regulatory scrutiny in specific regions, differing risk-benefit assessments, or a strategic decision by Regeneron to consolidate efforts on the global OPTIMA trial until more clarity on the safety profile is achieved.

5.4. Reasons for Trial Pauses/Withdrawals

As mentioned, dosing in the LUMINA-1 trial was paused by Regeneron following reports of the fatal serious adverse events (the five deaths) that occurred during the open-label extension. This action was taken to facilitate a thorough investigation into whether these events were directly related to Garetosmab treatment.[18] The withdrawal of the Japanese Phase 3 trial (NCT04577820) occurred in the context of these evolving safety concerns. These events underscore the rigorous safety oversight in clinical development and the complex decisions faced by pharmaceutical companies when serious adverse events emerge, particularly in studies involving rare diseases with high background morbidity and mortality.

Table 3: Overview of Key Clinical Trials for Garetosmab in FOP

Trial ID (Name)	Phase	Status	Key Objectives	Primary Efficacy Endpoints (Examples)	Brief Summary of Key Efficacy Results	Key Safety Findings/Concerns
NCT03188666 (LUMINA-1)	2	Completed	Efficacy and safety in adult FOP patients	Change in total lesion activity (18F-NaF PET-CT) at 28 weeks	~25% reduction in total lesion activity (p=0.0741); ~90% reduction in new HO lesions; 50% reduction in patient-reported flare-ups. No effect on existing mature HO. 2	Common AEs: epistaxis, madarosis, skin/soft tissue infections. Five deaths in OLE, causality to drug unconfirmed but not ruled out; led to trial pause. 2
NCT05318240 (OPTIMA)	3	Ongoing	Confirm suppression of new HO, reduce disease progression	New HO volume, disease progression markers	Results not yet available. Builds on LUMINA-1 findings. 2	Safety profile under continued evaluation.
NCT04577820 (Japanese Adult FOP Patients Study)	3	Withdrawn	Efficacy and safety in Japanese adult FOP patients	Not applicable	Not applicable due to withdrawal. 1	Not applicable due to withdrawal. Withdrawal likely influenced by LUMINA-1 safety signals or strategic decisions.

6. Exploration of Garetosmab in Other Therapeutic Areas

Beyond its primary investigation for FOP, Garetosmab is also being evaluated for its therapeutic potential in other conditions, most notably obesity. This expansion reflects a growing understanding of Activin A's role in broader physiological processes, including muscle metabolism and body composition.

6.1. Obesity

The rationale for exploring Garetosmab in obesity stems from preclinical and early clinical evidence suggesting that Activin A, along with GDF8 (myostatin), acts as a key negative regulator of skeletal muscle mass.[22] Blockade of these pathways has been shown to increase muscle mass and concomitantly decrease fat mass. The activin A pathway's potential to modulate metabolic processes is therefore a subject of active investigation.[2] This research is particularly relevant as many weight-loss interventions, including highly effective GLP-1 receptor agonists, can lead to undesirable loss of lean muscle mass along with fat. Therapies that could preserve or even increase muscle mass while promoting fat loss would represent a significant advance in obesity management.

Several clinical trials are assessing Garetosmab in the context of obesity and body composition:

• NCT02943239 (Phase 1, Completed): This randomized, double-blind, placebo-controlled Phase 1 trial evaluated the safety, tolerability, pharmacokinetics, and pharmacodynamics of trevogrumab (a GDF8-neutralizing antibody) and Garetosmab (an Activin A-neutralizing antibody), administered alone or in combination, to postmenopausal females.[22] The study found that combined blockade of GDF8 and Activin A led to dose-dependent, persistent, and greater-than-additive (synergistic) increases in muscle mass, accompanied by reductions in fat mass. These clinical effects on body composition paralleled the serum exposure of the monoclonal antibodies. The results from this trial provided strong human proof-of-concept that GDF8 and Activin A are dominant negative regulators of muscle mass in humans and that their combined blockade could be a promising therapeutic strategy for conditions involving muscle atrophy or for improving body composition in obesity.[22] This successful translation of preclinical findings to human pathophysiology is a direct driver for subsequent, larger combination studies.
• NCT06299098 (Phase 2, Enrolling): Titled "A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients With Obesity for Weight Loss and Fat Loss," this Phase 2 trial is actively enrolling participants.[13] The study, running from March 2024 to May 2026, aims to enroll 999 participants, including adults with obesity (Body Mass Index ≥30 kg/m2) and healthy participants (BMI ≥18 and ≤32 kg/m2 for Part A). The trial is structured in three parts (A, B, and C) and will evaluate various combinations of Garetosmab, trevogrumab, semaglutide (Wegovy®), and matching placebos. Part A focuses on safety and tolerability in healthy participants, while Parts B and C aim to assess the safety and efficacy of the investigational drug combinations with semaglutide in participants with obesity.[23] This trial represents a significant strategic interest in combining muscle-anabolic effects of Activin A/GDF8 inhibition with the potent weight-loss effects of GLP-1 receptor agonists.
• NCT06970405 (Phase 1, Not Yet Recruiting): This planned Phase 1 trial, titled "Study of Safety and Effects of Garetosmab in Healthy Obese Men and Post-Menopausal Women," is expected to begin in May 2025.[13] It aims to further evaluate Garetosmab as a treatment for obesity.

The active and advancing clinical program for Garetosmab in obesity, particularly in combination regimens, suggests a significant strategic direction for Regeneron towards metabolic diseases. This could represent an effort to leverage the muscle-sparing or anabolic effects of Activin A inhibition to enhance the quality of weight loss achieved with existing therapies, tapping into a much larger market than FOP.

6.2. Other Potential Indications (Preclinical/No Development Reported)

Exploration of Garetosmab or Activin A inhibition extends to other areas, though these are generally at an earlier stage of investigation:

• Osteoporosis: Preclinical development has been reported for Garetosmab in osteoporosis.[13]
• Musculoskeletal disorders: No specific development has been reported for this broad category.[13]
• Anti-cancer activity: The potential for anti-cancer activity through Activin A inhibition has been noted as an area for study, given Activin A's roles in cell growth and differentiation.[11]
• COVID-19: One source mentions Garetosmab "acts on COVID-19 44".[11] However, this claim lacks substantiation within the provided materials and should be viewed with extreme caution, as it may be a database artifact or a highly speculative assertion.

These explorations highlight the pleiotropic nature of Activin A and the diverse therapeutic possibilities that might arise from its targeted inhibition, depending on the specific pathological context.

Table 4: Overview of Garetosmab Clinical Trials in Other Indications (Primarily Obesity)

Trial ID	Indication(s)	Phase	Status	Drugs Involved	Key Objectives	Brief Summary of Key Findings (if available)
NCT02943239	Body Composition, Muscle Atrophy (Postmenopausal Females)	1	Completed	Garetosmab, Trevogrumab, Placebo	Safety, tolerability, PK, PD (muscle/fat changes)	Combination Garetosmab + Trevogrumab led to synergistic increases in muscle mass and decreases in fat mass. 22
NCT06299098	Obesity, Weight Loss, Fat Loss	2	Enrolling (Mar 2024 - May 2026)	Garetosmab, Trevogrumab, Semaglutide, Placebos	Part A (Healthy): Safety/tolerability. Parts B & C (Obesity): Safety/efficacy with Semaglutide for weight/fat loss, muscle effects. 13	Results not yet available.
NCT06970405	Obesity	1	Not Yet Recruiting (Planned May 2025)	Garetosmab, Placebo	Safety and effects of Garetosmab in healthy obese men and post-menopausal women. 13	Results not yet available.

7. Regulatory Landscape and Designations

Garetosmab has received several regulatory designations aimed at facilitating its development for FOP, reflecting the severity and rarity of the condition and the high unmet medical need.

7.1. Orphan Drug Status

Garetosmab has been granted Orphan Drug designation for the treatment of Fibrodysplasia Ossificans Progressiva by both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).[7] This designation is conferred on drugs intended for rare diseases (affecting fewer than 200,000 people in the U.S., or not more than 5 in 10,000 in the EU) and provides incentives to sponsors, such as market exclusivity for a period post-approval, fee reductions, and regulatory assistance.

7.2. Fast Track Designation (FDA)

In 2017, the FDA granted Fast Track designation to Garetosmab for the prevention of heterotopic ossification in patients with FOP.[7] The Fast Track program is designed to facilitate the development and expedite the review of drugs that treat serious conditions and fill an unmet medical need, with the goal of getting important new drugs to patients earlier.

The combination of Orphan Drug and Fast Track designations underscores the regulatory acknowledgment of FOP's severity and the urgent requirement for effective treatments. While these designations provide a supportive framework and can accelerate interaction with regulatory agencies, they do not guarantee approval. The drug must still rigorously demonstrate a favorable benefit-risk profile through adequate and well-controlled clinical trials, a standard that became particularly pertinent with the emergence of safety concerns in the LUMINA-1 trial.

7.3. PRIME (Priority Medicines) Scheme (EMA)

The EMA's PRIME (Priority Medicines) scheme is designed to offer enhanced support for the development of medicines that target an unmet medical need, aiming to optimize development plans and speed up evaluation.[26] While Garetosmab, as a treatment for FOP, would theoretically align with the criteria for PRIME eligibility due to the significant unmet need, there is no direct confirmation in the available information that Garetosmab itself has received this designation.[13]

7.4. Regulatory Submissions and Interactions

Following the announcement of encouraging Phase 2 results from the LUMINA-1 trial in early 2020, Regeneron had indicated plans to discuss potential regulatory submissions with authorities.[8] This suggested an initial belief that the efficacy signal might be strong enough, and the unmet need profound enough, to explore accelerated approval pathways based on Phase 2 data—a strategy sometimes pursued for transformative therapies in severe rare diseases.

However, the subsequent pausing of the LUMINA-1 trial in late 2020 due to the patient deaths observed in the open-label extension [18] significantly impacted these plans. Such serious safety signals necessitate thorough investigation and would invariably lead to a re-evaluation of any aggressive regulatory timelines, likely shifting the reliance towards more comprehensive data from ongoing (e.g., OPTIMA) or future Phase 3 trials. The withdrawal of the planned Phase 3 trial in Japanese FOP patients (NCT04577820) [17] further complicates the global regulatory strategy. Data from local populations are often preferred or required by regional authorities like Japan's Pharmaceuticals and Medical Devices Agency (PMDA). The absence of this specific trial could mean that any future submission in Japan would need to rely more heavily on global trial data, potentially requiring additional bridging studies or justification.

8. Comparative Context: Other Therapies for FOP

The therapeutic landscape for FOP is evolving, with one approved treatment and several other investigational agents exploring different mechanisms of action.

8.1. Approved Treatments

Sohonos (palovarotene):

Palovarotene (brand name Sohonos) is the first and currently only FDA-approved treatment for FOP.9 It is approved to reduce the volume of new heterotopic ossification in adults and children (females aged 8 years and older, and males aged 10 years and older) with FOP.29

• Mechanism of Action: Palovarotene is an orally bioavailable, selective agonist of the retinoic acid receptor gamma (RARγ).[28] RARγ is an important regulator of skeletal development. Palovarotene's binding to RARγ activates retinoid signaling, which in FOP is understood to inhibit chondrogenesis, the precursor to endochondral bone formation. This is thought to occur by modulating aberrant signaling through both the Activin A-receptor pathway and the BMP-SMAD 1/5/8 pathway, ultimately reducing ALK2/SMAD-dependent chondrocyte differentiation and osteogenesis.[30]
• Efficacy: Clinical data showed that Sohonos treatment resulted in a 54% reduction in the annualized volume of new HO compared to untreated patients from a natural history study (NHS).[30] The annualized new HO volume in palovarotene-treated patients was approximately half of that observed in the NHS cohort.[30]
• Safety Profile: Palovarotene is associated with a significant number of warnings and precautions, reflecting its retinoid class effects and impact on growing bone [29]:
• Embryo-fetal toxicity: Palovarotene is contraindicated during pregnancy due to the risk of severe fetal harm. Females of reproductive potential must use highly effective contraception before, during, and for at least one month after discontinuing therapy.[29]
• Premature epiphyseal closure (PEC): This is an irreversible serious risk in growing pediatric patients. Regular monitoring of skeletal maturity (e.g., via hand/wrist and knee X-rays, growth curves) is required.[29]
• Mucocutaneous adverse effects: These are very common (reported in 98% of patients) and include dry skin, dry lips, dry eyes, alopecia (hair loss), pruritus, rash, and skin peeling. Prophylactic measures like emollients, sunscreens, and lip moisturizers are recommended. These effects can lead to dose reductions.[29]
• Bone health: Decreased vertebral bone mineral content, bone density, and bone strength, as well as an increased risk of radiologically observed vertebral fractures, have been reported. Periodic radiological assessment of the spine is recommended.[30]
• Psychiatric symptoms: New or worsening psychiatric symptoms, including depression, anxiety, mood alterations, and suicidal thoughts/behaviors, can occur. Monitoring is advised.[29]
• Vision problems: Night blindness (decreased ability to see in the dark) may occur; ophthalmological evaluation may be needed.[29]

The approval of palovarotene, despite its substantial safety concerns (particularly PEC in children and teratogenicity), underscores the high tolerance for risk by regulatory bodies and the FOP community when faced with such a devastating and progressive disease lacking other therapeutic options. This establishes a complex benchmark for any new investigational FOP therapy like Garetosmab. For Garetosmab to find a significant place, it would likely need to demonstrate either superior efficacy in preventing HO or, critically, a more favorable long-term safety and tolerability profile, especially concerning pediatric patients and chronic use.

8.2. Other Investigational Agents

Several other therapeutic strategies are or have been under investigation for FOP:

• Bisphosphonates (e.g., Etidronate): These agents primarily inhibit bone resorption.[9] Clinical data are generally outdated and limited. Some early case reports and small trials suggested a potential reduction in the density of ectopic ossifications or transient amelioration of inflammatory symptoms. However, they did not appear to significantly improve joint mobility, and new ossifications continued to occur. Adverse effects such as abdominal pain were noted.[9]
• Tofacitinib: A Janus kinase (JAK) inhibitor.[9] A retrospective observational study involving a small number of FOP patients with severe disease (who had not responded to standard treatments) suggested that tofacitinib reduced the frequency and severity of disease flares and improved joint mobility over a 24-month period. It was reported as well-tolerated in this cohort.[9]
• Saracatinib: A selective inhibitor of the ALK2 (ACVR1) kinase.[9] Preclinical studies demonstrated that saracatinib effectively blocked BMP signaling and prevented HO formation in mouse models of FOP. Having been previously tested in humans for other indications (e.g., oncology) with a known safety profile, saracatinib has been considered a promising candidate for drug repositioning in FOP treatment.[9]
• Imatinib: A tyrosine kinase inhibitor. Case reports in children with FOP suggested that imatinib treatment reduced the frequency and intensity of flare-ups, decreased swelling, and improved function.[9]
• Rapamycin (Sirolimus): An mTOR inhibitor. Its efficacy in FOP remains uncertain based on limited case report data.[9]
• Isotretinoin: A retinoid, similar in class to palovarotene. An older clinical trial suggested it might decrease the incidence of HO in previously unaffected anatomical regions if therapy was initiated before any bone formation occurred in that specific region. However, it did not prevent flare-ups in already affected areas, and some patients experienced a severe loss of joint mobility.[9]

The variety of mechanisms being explored—ranging from targeting the upstream ligand Activin A (Garetosmab), modulating nuclear receptor signaling (palovarotene, isotretinoin), directly inhibiting the mutant ALK2 kinase (saracatinib), to modulating inflammatory pathways (tofacitinib)—indicates that the FOP pathogenesis pathway offers multiple points for therapeutic intervention. This diversity also raises the possibility that future FOP management might involve personalized approaches or combination therapies, although this remains speculative based on current data. The approval of palovarotene has fundamentally shifted the FOP treatment paradigm from purely supportive care to active pharmacological intervention, setting a new context for the evaluation of all subsequent investigational drugs.

9. Summary, Unmet Needs, and Future Perspectives

9.1. Recap of Garetosmab's Profile and Clinical Findings

Garetosmab (REGN2477) is an investigational fully human IgG4κ monoclonal antibody developed by Regeneron Pharmaceuticals that specifically targets and neutralizes Activin A. Its primary therapeutic rationale in Fibrodysplasia Ossificans Progressiva (FOP) is to block the aberrant signaling cascade initiated by Activin A binding to the mutated ACVR1 (R206H) receptor, thereby preventing pathological heterotopic ossification (HO).

Pharmacokinetic studies have revealed nonlinear, target-mediated drug disposition (TMDD), typical for high-affinity monoclonal antibodies. Clinical development in FOP, principally through the Phase 2 LUMINA-1 trial, demonstrated promising efficacy signals, notably an approximate 90% reduction in the formation of new HO lesions and a significant decrease in patient-reported flare-ups. However, these encouraging findings were overshadowed by serious safety concerns, primarily five patient deaths that occurred during the open-label extension of LUMINA-1. While a direct causal link to Garetosmab was not definitively established, and the deaths were considered potentially consistent with FOP's natural history, causality could not be ruled out, leading to a trial pause and complicating the drug's development path. Other adverse events included madarosis and skin/soft tissue infections.

Despite these challenges, a Phase 3 trial (OPTIMA) in FOP is ongoing. Simultaneously, Garetosmab is being actively investigated for obesity, often in combination with other agents like trevogrumab (anti-GDF8) and semaglutide, with Phase 2 trials underway and further Phase 1 studies planned. This expansion leverages Activin A's role as a negative regulator of muscle mass, aiming to improve body composition.

9.2. Unmet Needs in FOP Management

Even with the approval of palovarotene, substantial unmet medical needs persist for individuals living with FOP:

• Improved Safety and Tolerability: There is a critical need for therapies with more favorable safety profiles, particularly concerning long-term administration and use in growing children, where palovarotene carries risks like premature epiphyseal closure.
• Addressing Existing Heterotopic Ossification: Current and most investigational therapies, including Garetosmab and palovarotene, primarily focus on preventing new HO. Effective treatments that can remodel, resorb, or functionally improve areas already affected by established ectopic bone are desperately needed.
• Enhanced Symptom Management: Beyond HO prevention, better management of chronic pain, acute inflammatory flare-ups, and the profound functional limitations imposed by FOP remains a priority.
• Therapeutic Options for All Patients: Options are needed for patients who may not respond adequately to, or cannot tolerate, existing approved therapies.
• Disease Modification Beyond HO: Strategies to address other systemic aspects of FOP, such as abnormal cartilage formation or growth plate dysplasia, would be beneficial.

9.3. Potential Role of Garetosmab in FOP Management and Other Indications

The future of Garetosmab in FOP is contingent upon the outcomes of the ongoing OPTIMA Phase 3 trial and a clearer resolution of the safety concerns raised in LUMINA-1. If a favorable benefit-risk profile can be unequivocally established for a specific patient population or under a defined dosing and monitoring strategy, Garetosmab could offer an important alternative mechanism of action for preventing new HO in FOP. Its distinct target (Activin A) compared to palovarotene (RARγ) might make it suitable for different patient subsets or stages of the disease. The central challenge remains navigating the narrow therapeutic window between its efficacy on new HO and the serious safety signals.

In the realm of obesity, Garetosmab, particularly in combination with agents like trevogrumab and semaglutide, holds potential to contribute to more effective and higher-quality weight loss by preserving or enhancing lean muscle mass while promoting fat reduction. Success in this much larger market could provide a significant alternative path for the Garetosmab program, irrespective of the FOP outcome, and underscores Regeneron's belief in the science of Activin A inhibition for metabolic and muscle benefits.

9.4. Ongoing Research and Future Directions

The path forward for Garetosmab involves several critical elements:

• OPTIMA Trial Results: The data from the OPTIMA Phase 3 trial in FOP will be paramount in determining Garetosmab's future in this indication.
• Safety Signal Resolution: Continued investigation and analysis of the safety signals from LUMINA-1, particularly the patient deaths, are essential to fully understand the risks associated with Garetosmab in FOP patients.
• Obesity Program Progression: Continued clinical evaluation in obesity through ongoing Phase 2 and planned Phase 1 studies will define its utility in metabolic disease.
• Long-Term Data: For both FOP and obesity, long-term follow-up data on efficacy and safety will be crucial, especially given the chronic nature of these conditions and the long-term administration of a biologic therapy.
• Biomarker Development: Further development and validation of biomarkers to predict patient response, monitor target engagement, or identify individuals at higher risk of adverse events could help optimize Garetosmab's use.

The limitations of current therapies for FOP in addressing established HO suggest that the long-term evolution of treatment may involve combination strategies or entirely novel therapeutic modalities, such as gene therapy.[9] If Garetosmab successfully navigates its current challenges and gains approval, it could become a valuable component within a more comprehensive and potentially multimodal FOP treatment paradigm. The journey of Garetosmab highlights the complexities and high stakes of developing therapies for severe rare diseases, as well as the potential for repurposing scientific insights into broader therapeutic applications.

Works cited

1. Garetosmab: Uses, Interactions, Mechanism of Action | DrugBank ..., accessed June 10, 2025, https://go.drugbank.com/drugs/DB16379
2. What clinical trials have been conducted for Garetosmab? - Patsnap Synapse, accessed June 10, 2025, https://synapse.patsnap.com/article/what-clinical-trials-have-been-conducted-for-garetosmab
3. What is Garetosmab used for? - Patsnap Synapse, accessed June 10, 2025, https://synapse.patsnap.com/article/what-is-garetosmab-used-for
4. Garetosmab: A Promising Treatment for Rare Bone Disorders and Obesity - Clinical trials, accessed June 10, 2025, https://clinicaltrials.eu/inn/garetosmab/
5. The effects of garetosmab in people with fibrodysplasia ossificans ..., accessed June 10, 2025, https://www.tandfonline.com/doi/pdf/10.2217/frd-2023-0028
6. (PDF) The effects of garetosmab in people with fibrodysplasia ossificans progressiva (FOP): A plain language summary of the LUMINA-1 study - ResearchGate, accessed June 10, 2025, https://www.researchgate.net/publication/379774853_The_effects_of_garetosmab_in_people_with_fibrodysplasia_ossificans_progressiva_FOP_a_plain_language_summary_of_the_LUMINA-1_study
7. Regeneron Announces Encouraging Garetosmab Phase 2 Results in Patients with Ultra-Rare Debilitating Bone Disease, accessed June 10, 2025, https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-encouraging-garetosmab-phase-2-results/
8. Regeneron's FOP Disease Treatment Reduces New Lesions by 90% - BioSpace, accessed June 10, 2025, https://www.biospace.com/regeneron-posts-strong-mid-stage-data-in-bone-disease-drug-plans-potential-regulatory-filing
9. Future of fibrodysplasia ossificans progressiva management: A ..., accessed June 10, 2025, https://mednexus.org/doi/10.1002/rai2.12168
10. Garetosmab (REGN 2477) | CAS 2097125-54-5 | AbMole BioScience, accessed June 10, 2025, https://www.abmole.com/products/garetosmab.html
11. Garetosmab | TGF-beta/Smad - TargetMol, accessed June 10, 2025, https://www.targetmol.com/compound/garetosmab
12. GARETOSMAB - precisionFDA, accessed June 10, 2025, https://precision.fda.gov/ginas/app/ui/substances/48180a47-5135-4787-bf08-1627517d74c9
13. Garetosmab - Regeneron Pharmaceuticals - AdisInsight - Springer, accessed June 10, 2025, https://adisinsight.springer.com/drugs/800047263
14. www.glpbio.com, accessed June 10, 2025, https://www.glpbio.com/kr/garetosmab.html#:~:text=Garetosmab%20(Synonyms%3A%20REGN%202477)&text=Garetosmab%20(REGN%202477)%20is%20a,are%20for%20research%20use%20only.
15. Anti-INHBA (Garetosmab biosimilar) mAb (HDBS0566) - Assay Genie, accessed June 10, 2025, https://www.assaygenie.com/anti-inhba-garetosmab-biosimilar-mab-hdbs0566/
16. Study: Regeneron's garetosmab reduces bone lesions in patients with fibrodysplasia ossificans progressiva - FirstWord Pharma, accessed June 10, 2025, https://firstwordpharma.com/story/4927817
17. Fibrodysplasia Ossificans Progressiva (FOP) (DBCOND0086420 ..., accessed June 10, 2025, https://go.drugbank.com/conditions/DBCOND0086420
18. Regeneron Hits Pause on LUMINA-1 Trial Due to Concerns with Garetosmab - BioSpace, accessed June 10, 2025, https://www.biospace.com/regeneron-hits-pause-on-lumina-1-trial-due-to-concerns-with-garetosmab
19. Regeneron slams the brakes on rare bone disease trial after patient deaths | Fierce Biotech, accessed June 10, 2025, https://www.fiercebiotech.com/biotech/regeneron-slams-brakes-rare-bone-disease-trial-after-patient-deaths
20. Regeneron's bone disease drug delivers in phase 2, poised for FDA filing | Fierce Biotech, accessed June 10, 2025, https://www.fiercebiotech.com/biotech/regeneron-s-bone-disease-drug-delivers-phase-2-poised-for-fda-filing
21. Regeneron Publishes Plain Language Summary of the LUMINA-1 Phase 2 Study in FOP, accessed June 10, 2025, https://www.ifopa.org/regeneron_lumina1_plain_language_summary
22. GDF8 and activin A are the key negative regulators of muscle mass in postmenopausal females: a randomized phase I trial - PubMed Central, accessed June 10, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC12075688/
23. A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients With Obesity for Weight Loss and Fat Loss - Clinical Trials | Regeneron Pharmaceuticals, accessed June 10, 2025, https://clinicaltrials.regeneron.com/clinical-trials/a0Mdy0000001AwdEAE/nct06299098
24. A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients With Obesity for Weight Loss and Fat Loss - Clinical Trials | Regeneron Pharmaceuticals, accessed June 10, 2025, https://clinicaltrials.regeneron.com/clinical-trials/a0MPr0000005iU3MAI/nct06299098
25. Garetosmab Not Yet Recruiting Phase 1 Trials for Obesity Treatment | DrugBank Online, accessed June 10, 2025, https://go.drugbank.com/drugs/DB16379/clinical_trials?conditions=DBCOND0015947&phase=1&purpose=treatment&status=not_yet_recruiting
26. PRIME: priority medicines - EMA - European Union, accessed June 10, 2025, https://www.ema.europa.eu/en/human-regulatory-overview/research-development/prime-priority-medicines
27. rare diseases Archives - The Antibody Society, accessed June 10, 2025, https://www.antibodysociety.org/tag/rare-diseases/
28. List of Fibrodysplasia Ossificans Progressiva Medications - Drugs.com, accessed June 10, 2025, https://www.drugs.com/condition/fibrodysplasia-ossificans-progressiva.html
29. Patient Information - About SOHONOS, accessed June 10, 2025, http://www.sohonos.com/patient-information-about-sohonos
30. About SOHONOS, accessed June 10, 2025, http://www.sohonos.com/hcp/what-could-new-ho-prevention-mean-your-patients-hcp